Matrix metalloproteinase‐1 and microRNA‐486‐5p in urinary exosomes can be used to detect early lung cancer: A preliminary report

Wataru Ando,Masaya Sogabe,Shigemi Ishikawa,Takayuki Uematsu,Hiroyuki Furuya,Hiroaki Yokomori,Yutaka Kohgo,Katsuya Otori,Tomoyuki Nakano,Shunsuke Endo,Hiroyoshi Tsubochi,Isao Okazaki
DOI: https://doi.org/10.3892/ol.2024.14261
2024-01-31
Oncology Letters
Abstract:The present study describes a novel molecular‐genetic method suitable for lung cancer (LC) screening in the work‐place and at community health centers. Using urinary‐isolated exosomes from 35 patients with LC and 40 healthy volunteers, the expression ratio of MMP‐1/CD63, and the relative expression levels of both microRNA (miRNA)‐21 and miRNA‐486‐5p were measured. MMP‐1/CD63 expression ratio was significantly higher in patients with LC than in the healthy controls {1.342 [95% confidence interval (CI): 0.890‐1.974] vs. 0.600 (0.490‐0.900); P<0.0001}. The relative expression of miRNA‐486‐5p in male healthy controls was significantly different from that in female healthy controls, whereas there was no significant difference in miRNA‐21. Receiver operating characteristic curve (ROC) analysis of MMP‐1/CD63 showed 92.5% sensitivity and 54.3% specificity, whereas miRNA‐486‐5p showed 85% sensitivity and 70.8% specificity for men, and 70.0% sensitivity and 72.7% specificity for women. The logistic regression model used to evaluate the association of LC with the combination of MMP‐1/CD63 and miRNA‐486‐5p revealed that the area under the ROC curve was 0.954 (95% CI: 0.908‐1.000), and the model had 89% sensitivity and 88% specificity after adjusting for age, sex and smoking status. These data suggested that the combined analysis of MMP‐1/CD63 and miRNA‐486‐5p in urinary exosomes may be used to detect patients with early‐stage LC in the work‐place and at community health centers, although confirmational studies are warranted.
oncology
What problem does this paper attempt to address?